Related Experiment Video
Updated: Jul 21, 2025
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
CLK2 and CLK4 are regulators of DNA damage-induced NF-κB targeted by novel small molecule inhibitors
Patrick Mucka1, Peter Lindemann2, Bartolomeo Bosco1
1Laboratory of Signal Transduction in Tumor Cells, Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany.
Abstract:
Transcription factor NF-κB potently activates anti-apoptotic genes, and its inactivation significantly reduces tumor cell survival following genotoxic stresses. We identified two structurally distinct lead compounds that selectively inhibit NF-κB activation by DNA double-strand breaks, but not by other stimuli, such as TNFα. Our compounds do not directly inhibit previously identified regulators of this pathway, most critically including IκB kinase (IKK), but inhibit signal transmission in-between ATM, PARP1, and IKKγ. Deconvolution strategies, including derivatization and in vitro testing in multi-kinase panels, yielded shared targets, cdc-like kinase (CLK) 2 and 4, as essential regulators of DNA damage-induced IKK and NF-κB activity. Both leads sensitize to DNA damaging agents by increasing p53-induced apoptosis, thereby reducing cancer cell viability. We propose that our lead compounds and derivatives can be used in context of genotoxic therapy-induced or ongoing DNA damage to increase tumor cell apoptosis, which may be beneficial in cancer treatment.
Insights
New compounds selectively inhibit NF-κB activation following DNA damage, sensitizing cancer cells to genotoxic therapy by increasing apoptosis. This offers a novel strategy to enhance cancer treatment efficacy.
Area of Science:
- Molecular Biology
- Cancer Research
- Drug Discovery
Background:
- Nuclear factor kappa B (NF-κB) activation promotes cancer cell survival.
- Inhibiting NF-κB can enhance tumor cell death after genotoxic stress.
Purpose of the Study:
- Identify novel compounds targeting NF-κB activation.
- Investigate compounds that specifically inhibit DNA damage-induced NF-κB signaling.
Main Methods:
- Screening of lead compounds for NF-κB inhibition.
- Investigating compound mechanism of action via kinase panels.
- Assessing compound effects on cancer cell apoptosis and viability.
Main Results:
- Two distinct lead compounds selectively inhibited NF-κB activation triggered by DNA double-strand breaks.
- Compounds target cdc-like kinases (CLK) 2 and 4, regulating DNA damage-induced NF-κB.
- Lead compounds increased p53-induced apoptosis and reduced cancer cell viability when combined with DNA damaging agents.
Conclusions:
- CLK2 and CLK4 are key regulators of DNA damage-induced NF-κB.
- Lead compounds and derivatives show potential for enhancing genotoxic cancer therapy.
- Targeting DNA damage-induced NF-κB offers a promising therapeutic strategy to increase tumor cell apoptosis.
More Related Videos
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
02:34Inhibition of Cdk Activity
02:04Co-activators and Co-repressors
01:31The Intrinsic Apoptotic Pathway
02:37DNA Damage can Stall the Cell Cycle
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...